The Only FDA Cleared Wearable for 24/7 Chronic Pain Relief
BOSTON--(BUSINESS WIRE)--
NeuroMetrix, Inc. (NASDAQ:NURO) today announced the full commercial
launch of Quell,
which is now available on the Company's product website at
QuellRelief.com and at select physicians' offices. Quell is an
easy-to-use, over-the-counter chronic pain relief device. This
first-of-its-kind wearable device utilizes NeuroMetrix's patented,
non-invasive nerve stimulation technology to provide 100 percent
drug-free chronic pain relief. It is designed for people with painful
diabetic neuropathy, sciatica, osteoarthritis and fibromyalgia, among
other conditions.
"There are an estimated 100 million people living with chronic pain in
the U.S., and many are not experiencing adequate relief with currently
available treatment options or want to avoid opioid medications that may
incur added risk and side effects," says Dr. Paul Christo, Pain
Specialist and Host of the nationally syndicated radio show Aches
and Gains. "I am excited by the possibilities non-medication options
like wearable transcutaneous electrical nerve stimulation (TENS) devices
can provide people living with chronic pain, particularly because they
do not carry a risk of opioid dependence and side effects, and do not
require invasive surgeries."
Worn just below the knee, Quell calibrates automatically for every user,
determining the ideal therapeutic intensity of electrical nerve
stimulation to provide optimal pain relief. Quell triggers a central
inhibition effect that "turns down the volume" of pain signals by
stimulating the sensory nerves, which causes the brain to release
endogenous opioids that ultimately reduce pain signal transmission.
Quell provides widespread pain relief and is more than twice as strong
as ordinary TENS devices, which typically provide only localized pain
relief.
New York native Jesse Alberio has been living with painful diabetic
neuropathy for over two years. After trying a number of different
medications to control the pain, he was still experiencing burning and
numbness in his lower extremities. "As a security supervisor and NYPD
auxiliary police member, I'm on my feet all day," states Alberio. "I
used to change my shoes up to five times a day to try to relieve the
pain in my feet and even occasionally took opioid pain medication, which
would make me feel groggy. Now, I have been using Quell daily and don't
feel the need to change my shoes—it has significantly reduced my pain, I
have been taking less medication and I am sleeping better."
A recent study
conducted by the National Sleep Foundation found that nearly one in four
people living with chronic pain reported having poor or very poor sleep
quality. Limitations of traditional transcutaneous nerve stimulation
devices leave chronic pain sufferers without relief at night; Quell is
the only FDA cleared device of its kind approved for use while sleeping.
A built-in accelerometer detects when a person is sleeping and then
automatically adjusts the level of therapy so it will not disturb their
sleep.
Micke Brown, a registered pain management nurse, nurse educator and
long-time advocate for people living with pain, started experiencing
knee and foot pain caused by osteoarthritis two years ago. "Trying to be
active while living with chronic pain can be extremely frustrating,"
said Brown. "Quell has provided me with an on-the-go pain management
solution that fits into my busy schedule and also offers the flexibility
for me to take medications on days that I need to—and less often
overall."
Quell received FDA clearance in July 2014 for chronic pain relief and
use during nighttime sleep without a prescription. The FDA submission
for Quell was based on its predecessor, SENSUS, which has provided over
2.5 million hours of therapy to chronic pain sufferers throughout the
United States. Quell does not have any side effects, but users may
experience mild skin irritation after prolonged use.
The Quell pre-order
campaign through Indiegogo met its $100,000 goal in just 1.5 days
and achieved pre-orders totaling 388% of the original goal at the end of
the one month campaign. To date, more than 2,000 Quell devices have been
ordered through the campaign as well as from pre-orders on the website
and phone number at 1-800-204-6577. Devices ordered through the
Indiegogo campaign began shipping on May 27.
People with existing, implanted devices that utilize electrical
stimulation—such as a pacemaker or defibrillator—should not use Quell.
All chronic pain patients experience pain differently and find different
pain management solutions effective. NeuroMetrix offers a 60-day money
back guarantee for people who purchase the Quell device directly from
the website at QuellRelief.com.
Talk to your doctor before you stop taking any medication while on Quell.
About NeuroMetrix
NeuroMetrix is a publicly traded (NASDAQ:NURO) innovative health-care
company that develops wearable medical technology and point-of-care
tests that help patients and physicians better manage chronic pain,
nerve diseases, and sleep disorders. The company is located in Waltham,
Massachusetts and was founded as a spinoff from the Harvard-MIT Division
of Health Sciences and Technology in 1996. For more information, please
visit www.QuellRelief.com
and www.NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150615005489/en/
Media Contact:
Cohn & Wolfe for NeuroMetrix
Laura
Wagstaff, 415-403-8313
laura.wagstaff@cohnwolfe.com
or
Investor
Relations Contact:
NeuroMetrix, Inc.
Thomas T. Higgins,
781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media